{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:39:58Z","timestamp":1787002798907,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PLATFORM is an adaptive phase II trial assessing maintenance therapies in advanced oesophagogastric adenocarcinoma (OGA). We evaluated maintenance capecitabine in patients with disease control after first-line chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HER2-negative patients with advanced OGA who had response or stable disease after 18 weeks of first-line chemotherapy were randomised (1:1) to surveillance or capecitabine. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between May 2015 and May 2024, 266 patients were randomised (129 surveillance, 137 capecitabine). Median follow up was 70.7 months. Capecitabine significantly improved PFS (HR 0.69; 95% CI 0.54\u20130.89;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), with median PFS of 5.0 vs 2.8 months. One-year PFS rates were 19.9% vs 6.8%; and two-year rates 8.1% vs 4.3%. No OS difference was observed (median OS: 10.5 vs 10.0 months; HR 0.87; 95% CI 0.67\u20131.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.143). One and two-year OS rates were similar (1-year: 44.1% vs 45.7%; 2-year: 18.8% vs 16.8%). Grade \u22653 adverse events were more frequent with capecitabine (46% vs 29%), with 21% experiencing grade 3 treatment related events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Maintenance capecitabine significantly prolonged PFS compared to surveillance, meeting the primary endpoint and supporting its use to extend disease control in advanced OGA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03448-4","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:00:27Z","timestamp":1776790827000},"page":"240-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2643-2196","authenticated-orcid":false,"given":"Anderley","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Cromarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Piadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Zhitkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cafferkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prantik","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2055-4572","authenticated-orcid":false,"given":"Russell","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Roques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Hewish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carys","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-3829","authenticated-orcid":false,"given":"Tom","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"3448_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin [Internet]"},{"key":"3448_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"3448_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"3448_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"3448_CR5","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"3448_CR6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2217\/fon-2018-0609","volume":"15","author":"K Kato","year":"2019","unstructured":"Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15:1057\u201366.","journal-title":"Future Oncol"},{"key":"3448_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"3448_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12876-020-01232-z","volume":"20","author":"D G\u00f3mez-Ulloa","year":"2020","unstructured":"G\u00f3mez-Ulloa D, Amonkar M, Kothari S, Cheung WY, Chau I, Zalcberg JR, et al. Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterol. 2020;20:133.","journal-title":"BMC Gastroenterol"},{"key":"3448_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol. 2022;33:244\u201358.","journal-title":"Ann Oncol"},{"key":"3448_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34:987\u20131002.","journal-title":"Ann Oncol"},{"key":"3448_CR11","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192\u2013237.","journal-title":"Ann Oncol"},{"key":"3448_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606. Ann Oncol. 2021;32:1475\u201395.","journal-title":"Ann Oncol"},{"key":"3448_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"3448_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"3448_CR15","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","volume":"27","author":"B Chibaudel","year":"2009","unstructured":"Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andr\u00e9 T, Bennamoun M, et al. Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727\u201333.","journal-title":"J Clin Oncol"},{"key":"3448_CR16","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"LHJ Simkens","year":"2015","unstructured":"Simkens LHJ, van Tinteren H, May A, ten Tije AJ, Creemers GJM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385:1843\u201352.","journal-title":"Lancet"},{"key":"3448_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103307","volume":"160","author":"G Roviello","year":"2021","unstructured":"Roviello G, Rodriquenz MG, Aprile G, D\u2019Angelo A, Roviello F, Nobili S, et al. Maintenance in gastric cancer: New life for an old issue? Crit Rev Oncol Hematol. 2021;160:103307.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3448_CR18","doi-asserted-by":"publisher","first-page":"S853","DOI":"10.1016\/j.annonc.2023.09.1428","volume":"34","author":"A Gordon","year":"2023","unstructured":"Gordon A, Fong CYK, Davidson M, Cromarty S, Kidd S, Piadel K, et al. 1515P Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial. Ann Oncol. 2023;34:S853\u20134.","journal-title":"Ann Oncol"},{"key":"3448_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103622","volume":"9","author":"C Fong","year":"2024","unstructured":"Fong C, Patel B, Peckitt C, Bourmpaki E, Satchwell L, Cromarty S, et al. Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study. ESMO Open. 2024;9:103622.","journal-title":"ESMO Open"},{"key":"3448_CR20","doi-asserted-by":"crossref","unstructured":"Gordon A, Cunningham D, Rajan Z, Fong C, Peckitt C, Satchwell L, et al. Maintenance capecitabine plus ramucirumab after first-line chemotherapy in patients with advanced esophagogastric adenocarcinoma: results from the randomized PLATFORM study. JCO Oncol Adv. 2025.","DOI":"10.1200\/OA-24-00073"},{"key":"3448_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"3448_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:19\u201333.","journal-title":"Ann Oncol"},{"key":"3448_CR23","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"3448_CR24","unstructured":"Lisa Hang N, McMillian N, MaryElizabeth Stein M, Ajani JA, D TA, Chair V, et al. NCCN Guidelines Version 4.2024 Gastric Cancer NCCN Evidence Blocks TM Continue NCCN Guidelines Panel Disclosures [Internet]. 2024. Available from: www.nccn.org\/patents"},{"key":"3448_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"3448_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F Wang","year":"2024","unstructured":"Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44:127\u201372.","journal-title":"Cancer Commun"},{"key":"3448_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10120-023-01424-y","volume":"27","author":"F Lordick","year":"2024","unstructured":"Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, et al. German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 2024;27:6\u201318.","journal-title":"Gastric Cancer"},{"key":"3448_CR28","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s10120-018-0809-y","volume":"21","author":"Z Lu","year":"2018","unstructured":"Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, et al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel\/capecitabine and cisplatin\/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21:782\u201391.","journal-title":"Gastric Cancer"},{"key":"3448_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.5230\/jgc.2023.23.e16","volume":"23","author":"GJ Lee","year":"2023","unstructured":"Lee GJ, Kim H, Cho SS, Park HS, An HJ, Woo IS, et al. A randomized phase III study of patients with advanced gastric adenocarcinoma without progression after six cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. J Gastric Cancer. 2023;23:315.","journal-title":"J Gastric Cancer"},{"key":"3448_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejca.2017.06.008","volume":"83","author":"SR Park","year":"2017","unstructured":"Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer. 2017;83:32\u201342.","journal-title":"Eur J Cancer"},{"key":"3448_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101572","volume":"8","author":"G Stocker","year":"2023","unstructured":"Stocker G, Lorenzen S, Ettrich T, Herz AL, Longo F, Kiani A, et al. S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma\u2013final results of the randomized AIO MATEO phase II trial. ESMO Open. 2023;8:101572.","journal-title":"ESMO Open"},{"key":"3448_CR32","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.annonc.2024.05.335","volume":"35","author":"A Damato","year":"2024","unstructured":"Damato A, Bilancia D, Iachetta F, Strippoli A, Filiali F, Casaretti R, et al. 421P Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)\/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016). Ann Oncol. 2024;35:S171. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.335.","journal-title":"Ann Oncol"},{"key":"3448_CR33","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1200\/JCO.20.00892","volume":"39","author":"M Moehler","year":"2021","unstructured":"Moehler M, Dvorkin M, Boku N, \u00d6zg\u00fcro\u011flu M, Ryu MH, Muntean AS, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol. 2021;39:966\u201377.","journal-title":"J Clin Oncol"},{"key":"3448_CR34","doi-asserted-by":"publisher","first-page":"13145","DOI":"10.1002\/cam4.5997","volume":"12","author":"F Ciardiello","year":"2023","unstructured":"Ciardiello F, Bang Y, Cervantes A, Dvorkin M, Lopez CD, Metges J, et al. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results. Cancer Med. 2023;12:13145\u201354.","journal-title":"Cancer Med"},{"key":"3448_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/S1470-2045(24)00580-1","volume":"25","author":"G Randon","year":"2024","unstructured":"Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1539\u201350.","journal-title":"Lancet Oncol"},{"key":"3448_CR36","doi-asserted-by":"publisher","first-page":"e194489","DOI":"10.1001\/jamaoncol.2019.4489","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer. JAMA Oncol. 2020;6:e194489.","journal-title":"JAMA Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03448-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T03:01:46Z","timestamp":1782702106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03448-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,20]]}},"alternative-id":["3448"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03448-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following conflict of interests. DC: Consulting or Advisory Role: OVIBIO Research Funding: Bayer (Inst), 4SC (Inst), Clovis Oncology (Inst), Lilly (Inst), Leap Oncology (Inst), Roche (Inst). AG: Honoraria: Servier. CF: Honoraria: BMS. MD: speakers fee from Takeda and Roche. TW: Honoraria: Pfizer, Ipsen, Bristol Myers Squibb, EUSA Pharma Consulting or Advisory Role: Pfizer, Ipsen, Merck Sharp & Dohme, Eisai Europe, Merck Research Funding: Bristol Myers Squibb (Inst), Pfizer (Inst), Ipsen (Inst), Merck Sharp & Dohme (Inst), Roche (Inst), Eisai (Inst) Travel, Accommodations, Expenses: EUSA Pharma, Bristol Myers Squibb, Ipsen Carys Morgan Travel, Accommodations, Expenses: Novartis. CM: Travel, Accommodations, Expenses: Novartis. SD: Speakers fee: BMS, Servier. AB: Honoraria: SERVIER Travel, Accommodations, Expenses: Servier. RP: Honoraria: Bristol Myers Squib, Servier Consulting or Advisory Role: Bristol-Myers Squib, Servier, BeiGene, Amgen, AstraZeneca, Astellas Pharma, Platinum Discovery Speakers\u2019 Bureau: Bristol Myers Squibb, Servier Research Funding: AstraZeneca, MSD Oncology (Inst), Merck Serono (Inst), Roche (Inst), Astellas Pharma (Inst), Moderna Therapeutics (Inst), Amgen (Inst), BioNTech SE (Inst), AbbVie (Inst), Astellas Pharma (Inst), Daiichi Sankyo\/AstraZeneca (Inst), Platinum Discovery (Inst) Travel, Accommodations, Expenses: Bristol Myers Squibb, BeiGene, MSD. SR: Honoraria: Bayer, Servier (I), Merck Serono, Incyte Consulting or Advisory Role: AstraZeneca, Bayer, Nordic Bioscience Speakers\u2019 Bureau: Takeda, Servier, Merck Serono, Incyte Travel, Accommodations, Expenses: Servier, MSD Oncology. NS: Honoraria: Merck Serono, Servier, Pierre Fabre, MSD Oncology, Pierre Fabre, Seagen, GlaxoSmithKline, Merck, Pierre Fabre, MSD Oncology, BMS, AstraZeneca, Daiichi Sankyo, Natera, Astellas Pharma, Tempus Consulting or Advisory Role: MSD Oncology, GlaxoSmithKline, Gilead Sciences, Seagen, Janssen, Takeda, Moderna Therapeutics, Bristol Myers Squibb, AstraZeneca Research Funding: Gilead Sciences (Inst) Travel, Accommodations, Expenses: MSD Oncology, Guardant Health, Servier, GlaxoSmithKline, Takeda, Bristol Myers Squibb Uncompensated Relationships: Guardant Health. IC: Honoraria: Servier, Bristol-Myers Squibb, Jazz Pharmaceuticals, Astellas Pharma, Daiichi Sankyo. Consulting or Advisory Role: OncXerna Therapeutics, Astellas Pharma, GlaxoSmithKline, Seagen, BioNTech SE, Takeda, Elevation Oncology, BeiGene, Jazz Pharmaceuticals, Gilead Sciences, Roche\/Genentech, Research Funding (Institution): Janssen-Cilag, Lilly. Travel, Accommodations, Expenses: BMS, Servier, Takeda, Jazz Pharmaceuticals. The remaining authors declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was obtained from the UK National Research Ethics Committee London Southeast (14\/LO\/1206) and the Medicines and Healthcare Products Regulatory Agency (Eudra CT Number: 2014-002169-30).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent for participation including publication of results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}